Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrafiltration Efficacy of IXC vs Icodextrin in PD
NCT04086212Phase 2Withdrawn
- Sponsor
- Iperboreal Pharma
- Start
- Oct 2019
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of xylitol, levocarnitine in end stage renal disease (ESRD), sponsored by Iperboreal Pharma. Planned start Oct 2019; status: withdrawn.
02
Drugs
xylitollevocarnitine
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT04086212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086212.